{"data":{"ModuleTitle":{"label":"Module Title","value":"Company Description"},"CompanyName":{"label":"Company Name","value":"DiaMedica Therapeutics Inc."},"Symbol":{"label":"Symbol","value":"DMAC"},"Address":{"label":"Address","value":"TWO CARLSON PARKWAY,SUITE 260 SUITE 210, MINNEAPOLIS, Minnesota, 55447, United States"},"Phone":{"label":"Phone","value":"+1 763 612-6755"},"Industry":{"label":"Industry","value":"Biotechnology: Pharmaceutical Preparations"},"Sector":{"label":"Sector","value":"Health Care"},"Region":{"label":"Region","value":"North America"},"CompanyDescription":{"label":"Company Description","value":"DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is principally engaged in the business activity of developing treatments for unmet clinical needs or where no therapies are available with a primary focus on chronic kidney disease and acute ischemicstroke. Its pipeline product DM199 is a recombinant form of human tissue kallikrein-1."},"CompanyUrl":{"label":"Company Url","value":"https://www.diamedica.com"},"KeyExecutives":{"label":"Key Executives","value":[{"name":"Ambarish Shah","title":"Chief Technology Officer"},{"name":"Lorianne K. Masuoka","title":"Chief Medical Officer"},{"name":"Rick John Pauls","title":"President. Chief Executive Officer & Director"}]}},"message":null,"status":{"rCode":200,"bCodeMessage":null,"developerMessage":null}}